Tumor microenvironment adrenergic nerves blockade liposomes for cancer therapy

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Adrenergic nerves within tumors play a crucial role in cancer initiation, angiogenesis, and immune suppression.
• Targeting these nerves presents a potential strategy for novel cancer therapies.

Purpose of the Study:

• To evaluate the efficacy of propranolol liposomes (Lipo pro) in modulating tumor adrenergic nerve signaling for cancer treatment.
• To assess the therapeutic potential of Lipo pro in various cancer types and in combination with chemotherapy.

Main Methods:

• Administration of propranolol liposomes (Lipo pro) to modulate tumor adrenergic nerve signaling.
• Evaluation of Lipo pro's effects on tumor microenvironment, including adrenergic nerves and vasculature.
• Assessment of therapeutic outcomes in preclinical models of prostatic cancer, pancreatic ductal adenocarcinoma, and melanoma.
• Comparison of Lipo pro monotherapy versus combination therapy with chemotherapy.

Main Results:

• Lipo pro effectively regulated tumor microenvironment adrenergic nerves, angiogenesis, and immunosuppression.
• Significant therapeutic effects were observed in prostatic cancer, pancreatic ductal adenocarcinoma, and melanoma models.
• Combination therapy with Lipo pro and chemotherapy demonstrated superior tumor growth and metastasis inhibition, prolonging survival.

Conclusions:

• Targeting tumor adrenergic nerve signaling with Lipo pro is a viable strategy for cancer therapy.
• Lipo pro exhibits significant therapeutic potential across multiple cancer types.
• Combination therapy enhances treatment efficacy, offering a promising approach for improved patient outcomes.